Table 3.
Association of primary patency with baseline characteristics after propensity score matching.
| Univariate analysis | Multivariate analysis | |
|---|---|---|
| Patient characteristics | ||
| Age | 1.0 (1.0–1.0) | – |
| Female gender | 1.2 (0.9–1.5) | – |
| Ambulatory | 0.8 (0.6–1.2) | – |
| Hypertension | 1.1 (0.8–1.4) | – |
| Dyslipidemia | 1.1 (0.9–1.3) | – |
| Diabetes mellitus | 1.4 (1.1–1.8)*** | 1.4 (1.1–1.7)** |
| Regular dialysis | 1.7 (1.4–2.2)****** | 1.4 (1.1–1.8)* |
| Current smoking | 1.0 (0.8–1.3) | – |
| Cilostazol | 0.6 (0.5–0.8)****** | 0.6 (0.5–0.8)***** |
| Statin | 1.0 (0.8–1.2) | – |
| ACEI or ARB | 0.8 (0.6–1.0)* | 0.9 (0.7–1.1) |
| CLI | 1.5 (1.2–1.9)**** | 1.2 (0.9–1.6) |
| Lesion characteristics | ||
| TASC II C/D | 1.6 (1.2–2.1)**** | – |
| Lesion length | 1.0 (1.0–1.0)***** | – |
| ⩽150 mm | 0.7 (0.5–1.0)* | – |
| ⩽100 mm | 0.7 (0.5–0.9)*** | 0.8 (0.6–1.1) |
| ⩽50 mm | 0.7 (0.6–0.9)*** | – |
| Reference diameter | 0.8 (0.7–0.9)***** | – |
| ⩾7 mm | 0.8 (0.5–1.3) | – |
| ⩾6 mm | 0.7 (0.6–0.9)* | 0.8 (0.6–1.0) |
| ⩾5 mm | 0.8 (0.6–1.0) | – |
| Calcification | 1.5 (1.2–1.9)**** | 1.1 (0.9–1.5) |
| CTO | 1.4 (1.1–1.7)*** | 1.3 (1.1–1.7)* |
| Poor run-off | 1.2 (1.0–1.5) | – |
| Procedure details | ||
| Balloon angioplasty | 1.2 (1.0–1.5) | – |
| IVUS use | 0.6 (0.4–0.8)**** | 0.5 (0.4–0.7)***** |
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CLI: critical limb ischemia; TASC: Trans-Atlantic Inter-Society Consensus; CTO: chronic total occlusion; IVUS: intra-vascular ultra-sonography.
Data are hazard ratios and 95% confidence intervals.
*
p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001, *****p < 0.0005, ******p < 0.0001.